Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating consensus for Q4 and FY24, the analyst tells investors. The firm is raising its price target on the stock to reflect updated sales expectations in cystic fibrosis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $407 from $402 at RBC Capital
- Vertex Pharmaceuticals’ Journavx: Strategic Market Adoption and Growth Outlook
- Vertex Pharmaceuticals price target raised to $459 from $450 at Morgan Stanley
- Vertex Pharmaceuticals: Mixed Financial Performance and Future Prospects Lead to Hold Rating
- Vertex Pharmaceuticals: Hold Rating Due to Mixed Outlook and Generic Competition Risks